"March 7, 2013 -- An FDA panel voted to stop recommending calcitonin salmon for the treatment of osteoporosis in women who are at least five years past menopause.
The committee voted 12-9 against continued marketing of the drug, citing"...
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates.
Summary of Most Frequently Reported Treatment Emergent Adverse
Experiences/Medical Events ( ≥ 5%) By Treatment Groups
|AE per Body System||Menostar 14 mcg/day
|Body as a Whole||95 (46%)||100 (48%)|
|Abdominal Pain||17 (8%)||17 (8%)|
|Accidental Injury||29 (14%)||23 (11%)|
|Infection||11 (5%)||10 (5%)|
|Pain||26 (13%)||26 (12%)|
|Cardiovascular||20 (10%)||19 (9%)|
|Digestive System||52 (25%)||44 (21%)|
|Constipation||11 (5%)||6 (3%)|
|Dyspepsia||11 (5%)||9 (4%)|
|Metabolic and Nutritional Disorders||25 (12%)||22 (11%)|
|Musculoskeletal System||54 (26%)||51 (24%)|
|Arthralgia||24 (12%)||13 (6%)|
|Arthritis||11 (5%)||15 (7%)|
|Myalgia||10 (5%)||6 (3%)|
|Nervous System||30 (14%)||23 (11%)|
|Dizziness||11 (5%)||6 (3%)|
|Repiratory System||62 (30%)||67 (32%)|
|Bronchitis||12 (6%)||9 (4%)|
|Upper Respiratory Infection||33 (16%)||35 (17%)|
|Skin and Appendages||50 (24%)||54 (26%)|
|Application Site Reaction||18 (9%)||18 (9%)|
|Breast Pain||10 (5%)||8 (4%)|
|Urogenital System||66 (32%)||40 (19%)|
|Cervical Polyps||13 (6%)||4 (2%)|
|Leukorrhea||22 (11%)||3 (1%)|
The following additional adverse reactions have been reported with estrogens and/or progestin therapy.
Changes in vaginal bleeding pattern and abnormal withdrawal bleeding or flow; breakthrough bleeding; spotting; dysmenorrhea; increase in size of uterine leiomyomata; vaginitis, including vaginal candidiasis; change in amount of cervical secretion; changes in cervical ectropion; ovarian cancer; endometrial hyperplasia; endometrial cancer.
Retinal vascular thrombosis; intolerance to contact lenses.
Central nervous system
Increase or decrease in weight; reduced carbohydrate tolerance; aggravation of porphyria; edema; arthalgias; leg cramps; changes in libido; anaphylactoid/ana-phylactic reactions including urticaria and angioedema; hypocalcemia; exacerbation of asthma; increased triglycerides.
Read the Menostar (estradiol transdermal system) Side Effects Center for a complete guide to possible side effects
Drug/Laboratory Test Interactions
- Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.
- Increased thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels as measured by protein-bound iodine (PBI), T4 levels (by column or by radioimmunoassay) or T3 levels by radioim-munoassay. T3 resin uptake is decreased, reflecting the elevated TBG. Free T4 and free T3 concentrations are unaltered. Patients on thyroid replacement therapy may require higher doses of thyroid hormone.
- Other binding proteins may be elevated in serum (i.e., corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG) leading to increased total circulating corticosteroids and sex steroids, respectively. Free hormone concentrations may be decreased. Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-l-antitrypsin, ceruloplasmin).
- Increased plasma HDL and HDL2 subfraction concentrations, reduced LDL cholesterol concentration, and in oral formulations increased triglyceride levels.
- Impaired glucose tolerance.
- Reduced response to metyrapone test.
Last reviewed on RxList: 3/27/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Menostar Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get tips and advances in treatment.